Alcon Shareholders' Short Stick in Novartis Deal
Deal creates a Swiss eye-care giant, but blinds some investors.
Novartis (NVS) announced Monday morning that it was cashing in its right to buy the remainder of Nestle's eye-care business Alcon (ACL) it didn't already own. And it threw a merger proposal on the table for the minority public stake that could bring the deal's total value to $49.7 billion once all is said and done. (See, What the Top Ten 2009 Pharma Deals Say About 2010.)
The deal, which includes the 25% stake that Novartis bought in April 2008 for $10.4 billion, or $143 per share, allows the Swiss pharma giant to easily snag Nestle's remaining 52% stake of Alcon for another $28.1 billion, or $180 per share. This move comes as no surprise to anyone -- Novartis was given the option to acquire the rest of Nestle's share of Alcon any time between January 2010 and July 2011. Investors were tipped off that the Swiss pharma was ready to pounce early when it converted its financial reporting system at the end of last year to exclude non-cash charges like M&A activity.
But the major shocker is Novartis's willingness to put a deal on the table for the 23% minority public share of Alcon, which the pharmaceutical company had said it wasn't all that interested in. And from most points of view, the offer -- at only $153 per share and a 15% discount to the Nestle offer -- is nothing short of offensive to Alcon shareholders.
Normally, investors would assume the $153 per share offer was just a jumping-off point and that negotiations will lead to a better deal for them, but Novartis has some tricky merger laws on its side that will allow it to by-pass negations altogether.
Once Novartis is the majority stakeholder of the world's leading eye-care company, with 77% ownership of the company, it can effectively force the acquisition of the minority stake at whatever price it wants. Swiss law (both Novartis and Alcon are Swiss companies) allows Novartis to use its new majority stake to vote on the merger (this is a far cry form how minority interest transactions are handled in the US.).
So, Alcon investors should be pretty outraged (considering the stock was closing above $160 just a week prior to today's announcement), but what should Novartis shareholder's do?
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Daily Recap Newsletter